BIOFRONTERA INC (BFRI)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
$0.87-6.29%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
Research Workspace
Put BFRI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 18% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskBFRI’s sBCC treatment launch and pipeline expansion support growth, though earnings remain unprofitable. Revenue grew 32.9% year over year, and Q2 FY2026 earnings beat consensus. The shares trade at 0.3× sales versus a 2.4× peer median. The price reflects modest growth expectations, below our forecast. Our model puts the next-quarter miss probability near 47%. Unprofitability and the wide peer gap leave the sales-based valuation open to challenge. Peer multiples imply a price about 89% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. BFRI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering BFRI (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare BFRI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BFRI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put BFRI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand clinical pipeline and prepare for sBCC FDA approval and launch
FDA approval supports sBCC pipeline expansion and revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Increase revenue through growth in Ameluz® unit volume and price increases
Strong Ameluz growth supports revenue increase objective.
Advances: Increase revenue
PDUFA date and product launch support revenue growth.
Advances: Increase revenue
Earnings beat indicates improved financial performance and revenue growth.
Advances: Increase revenue
Earnings beat indicates strong revenue growth potential.
Rating cut indicates reduced confidence in financial performance.